Received May 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 445TK | IM |
body aches; 7 nights of fevers; chills; This non-serious case was reported by a consumer and described the occurrence of general body pain in a 54-year-old female patient who received Herpes zoster (Shingrix) (batch number 445TK, expiry date 09-AUG-2026) for prophylaxis. Concurrent medical conditions included anxiety. Concomitant products included sertraline hydrochloride (Sertraline). On 25-APR-2025, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. In APR-2025, an unknown time after receiving Shingrix, the patient experienced general body pain (Verbatim: body aches), fever (Verbatim: 7 nights of fevers) and chills (Verbatim: chills). The outcome of the general body pain, fever and chills were not resolved. It was unknown if the reporter considered the general body pain, fever and chills to be related to Shingrix. It was unknown if the company considered the general body pain, fever and chills to be related to Shingrix. Additional Information: GSK receipt date: 05-MAY-2025 The patient experienced 7 nights of fever, chills and body aches.
Anxiety
Sertraline